Evidence map›Paper›PMID 30027600›Full record

Trial reportJournal of the International AIDS Society2018

The impact of population dynamics on the population HIV care cascade: results from the ANRS 12249 Treatment as Prevention trial in rural KwaZulu-Natal (South Africa).

Joseph Larmarange, Mamadou Hassimiou Diallo, Nuala McGrath, Collins Iwuji, Mélanie Plazy, Rodolphe Thiébaut, Frank Tanser, Till Bärnighausen, Deenan Pillay, François Dabis and 2 more

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of the International AIDS Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01509508 (A Cluster Randomised Trial Comparing the Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence. The ARNS 12249 TasP), which is not on this map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01509508 nacompletednot on this map

A Cluster Randomised Trial Comparing the Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence. The ARNS 12249 TasP (Treatment as Prevention) Trial in Hlabisa Sub-district, KwaZulu-Natal, South Africa.

TypeinterventionalSponsorANRS, Emerging Infectious DiseasesRan2012 to 2016Enrolled28,153ConditionsHIV InfectionArmsImmediate ARV treatment initiation with TDF/FTC/EFV, South African recommendation guided ARV (TDF/FTC/EFV) initiation
3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Prevention, treatment and cure of HIV infection.Nature reviews. Microbiology · 2023
    Review
  14. Article
  15. Article
  16. Article
  17. Mobility and ART retention among men in Malawi: a mixed-methods study.Journal of the International AIDS Society · 2023
    Article
  18. Mobility and HIV care engagement: a research agenda.Journal of the International AIDS Society · 2023
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Joseph LarmarangeCentre Population et Développement, Institut de Recherche pour le Développement, Université Paris Descartes, Inserm, Paris, France.
Mamadou Hassimiou DialloCentre Population et Développement, Institut de Recherche pour le Développement, Université Paris Descartes, Inserm, Paris, France.
Nuala McGrathSchool of Nursing and Public Health, Africa Health Research Institute, University of KwaZulu-Natal, KwaZulu-Natal, South Africa.
Collins IwujiAfrica Health Research Institute, KwaZulu-Natal, South Africa.
Mélanie PlazyISPED, Inserm, Bordeaux Population Health Research Center, Université de Bordeaux, Bordeaux, France.
Rodolphe ThiébautISPED, Inserm, Bordeaux Population Health Research Center, Université de Bordeaux, Bordeaux, France.
Frank TanserSchool of Nursing and Public Health, Africa Health Research Institute, University of KwaZulu-Natal, KwaZulu-Natal, South Africa.
Till BärnighausenAfrica Health Research Institute, KwaZulu-Natal, South Africa.
Deenan PillayAfrica Health Research Institute, KwaZulu-Natal, South Africa.
François DabisISPED, Inserm, Bordeaux Population Health Research Center, Université de Bordeaux, Bordeaux, France.
Joanna Orne-GliemannISPED, Inserm, Bordeaux Population Health Research Center, Université de Bordeaux, Bordeaux, France.
ANRS 12249 TasP Study Group

Funding

Wellcome Trust
6 · The paper itself

Abstract

introductionThe universal test and treat strategy (UTT) was developed to maximize the proportion of all HIV-positive individuals on antiretroviral treatment (ART) and virally suppressed, assuming that it will lead to a reduction in HIV incidence at the population level. The evolution over time of the cross-sectional HIV care cascade is determined by individual longitudinal trajectories through the HIV care continuum and underlying population dynamics. The purpose of this paper is to quantify the contribution of each component of population change (in- and out-migration, HIV seroconversion, ageing into the cohort and definitive exit such as death) on the HIV care cascade in the context of the ANRS 12249 Treatment as Prevention (TasP) cluster-randomized trial, investigating UTT in rural KwaZulu-Natal, South Africa, between 2012 and 2016.

methodsHIV test results and information on clinic visits, ART prescriptions, viral load and CD4 count, migration and deaths were used to calculate residency status, HIV status and HIV care status for each individual on a daily basis. Position within the HIV care continuum was considered as a score ranging from 0 (undiagnosed) to 4 (virally suppressed). We compared the cascade score of each individual joining or leaving the population of resident adults living with HIV with the average score of their cluster at the time of entry or exit. Then, we computed the contribution of each entry or exit on the average cascade score and their annualized total contribution, by component of change.

resultsWhile the average cascade score increased over time in all clusters, that increase was constrained by population dynamics. Permanent exits and ageing into the people living with HIV cohort had a marginal effect. Both in-migrants and out-migrants were less likely to be retained at each step of the HIV care continuum. However, their overall impact on the cross-sectional cascade was limited as the effect of in- and out-migration balanced each other. The contribution of HIV seroconversions was negative in all clusters.

conclusionsIn a context of high HIV incidence, the continuous flow of newly infected individuals slows down the efforts to increase ART coverage and population viral suppression, ultimately attenuating any population-level impact on HIV incidence. CLINICAL TRIAL NUMBER: NCT01509508 (clinicalTrials.gov)/DOH-27-0512-3974 (South African National Clinical Trials Register).

Indexed as

Continuity of Patient CarePopulation DynamicsTime-to-TreatmentAdultAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountCohort StudiesCross-Sectional StudiesFemaleHIV InfectionsHumansIncidenceMaleMiddle AgedPrevalenceAnti-HIV AgentsCross-sectional cascadeHIV care continuumMigrationPopulation dynamicsPublic healthRural South AfricaStructural drivers

Identifiers

PMID30027600
PMCPMC6053480

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.